A research team at the Korea Advanced Institute of Science and Technology (KAIST) has developed a new artificial intelligence model that could change how personalized cancer vaccines are designed. For decades, most cancer vaccine strategies have focused on training the immune system’s T cells to attack tumors quickly and directly, which can shrink tumors but […]
Researchers from Israel’s Weizmann Institute of Science have unveiled a promising immunotherapy strategy that targets drug-resistant cancers by exploiting the very genetic mutations responsible for treatment failure. The approach centers on a computational tool called SpotNeoMet, which scans large patient datasets to identify recurrent resistance mutations that generate neo-antigens, unique protein fragments displayed exclusively […]
In a previous article, cancer reversion was introduced as the idea that malignant cells can be pushed back toward a more normal, less aggressive state instead of simply being destroyed. That earlier discussion focused mainly on epigenetic plasticity, differentiation therapy, and microenvironmental modulation as ways to coax cancer cells into behaving more like healthy tissue. […]
A team of scientists in China has found a way to turn the same type of cells that cause allergies into a new kind of weapon against cancer. Their work suggests that the body’s fastest immune reaction, normally blamed for hives and asthma, could be redirected to wake up the immune system inside tumors and […]
Logic-gated DARPins are a promising new tool in cancer treatment that could make immunotherapy safer and more effective for hard-to-treat solid tumors. They work by only turning on immune cells called T cells when two specific markers are found together on cancer cells, preventing dangerous overactivation in healthy parts of the body. What makes them […]
A clinical trial at Zhongda Hospital in China is testing a combination of fasudil hydrochloride, a Rho-associated kinase (ROCK) inhibitor, with PD-1 immune checkpoint blockade in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). This Phase II open-label trial enrolls patients aged 18 to 85 years who have progressed after at least one docetaxel-containing chemotherapy […]
KLS-3021 is a novel oncolytic virus therapy developed for the treatment of prostate cancer. It employs a recombinant vaccinia virus engineered to selectively infect and destroy cancer cells while activating the immune system to target tumors more effectively. The virus carries three therapeutic genes: PH-20, which degrades the extracellular matrix to facilitate viral spread and […]
Researchers at the University of California, Irvine have developed an innovative cancer immunotherapy called GlyTR, a new class of treatment that uses a “velcro-like” mechanism to target sugar molecules abundantly present on cancer cells. Their findings were published in September 2025 in the prestigious journal Cell, marking a significant advancement in cancer immunotherapy. Traditional immunotherapies […]
A study from The Ohio State University Comprehensive Cancer Center has illuminated a critical reason why cancer immunotherapy often fails: T-cell exhaustion driven by a novel stress pathway called TexPSR (proteotoxic stress response in T-cell exhaustion). Published in the prestigious journal Nature, this discovery reveals a proteotoxic shock in exhausted T cells caused by the […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy